{"product_id":"medpace-marketing-mix","title":"Medpace Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Medpace’s product offerings, pricing architecture, channel strategy, and promotional mix combine to support its clinical research leadership—this preview highlights key drivers, but the full 4Ps Marketing Mix Analysis delivers a presentation-ready, editable report with data-backed insights, tactical examples, and strategic recommendations to save you hours of work and power client briefs, coursework, or executive planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFull-Service Clinical Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace offers end-to-end Phase I–IV clinical development services for biotech and pharma, managing 5,000+ global studies to date and supporting 2024 revenues of $1.3B; their integrated model bundles therapeutic-area experts, centralized data management, regulatory affairs, and site networks to cut timelines—clients report median study startup reduced by ~20%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Therapeutic Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace employs 1,200+ physicians and PhDs, delivering deep scientific expertise in oncology, cardiology, and metabolic diseases—areas that drove 62% of its 2024 clinical revenues of $1.1B. This high-science staff enables precise execution of complex protocols and recruitment in niche patient populations, reducing protocol amendments by 18% versus industry averages. Their regulatory know-how supports faster IND submissions and fewer inspection findings, lowering trial delays and cost overruns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Laboratory Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace operates wholly-owned central laboratories delivering standardized bioanalytical testing across 40+ global trial sites, processing over 3 million assays annually (2024), which cuts inter-lab variability and supports regulatory submissions. These labs provide pathology, genomics, and specialty testing—next-generation sequencing and biomarker panels—critical to data accuracy and FDA\/EMA compliance. Embedding labs in the CRO reduces sample transit time by ~30% versus third-party networks, lowering protocol deviations and boosting data reliability. Integrated lab revenue contributed an estimated 12% of Medpace’s 2024 service revenue, strengthening control over quality and timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Regulatory Consulting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedpace Integrated Regulatory Consulting gives strategic guidance to navigate FDA and EMA rules, cutting average review timelines; clients report up to 20% faster IND\/CTA progression in 2024 benchmarks.\u003c\/p\u003e\n\u003cp\u003eConsultants handle document prep, submission strategy, and direct health-authority liaison—reducing resubmissions by ~30% and lowering approval costs for clients by an estimated $1.2M per program.\u003c\/p\u003e\n\u003cp\u003eThis service targets small‑to‑mid biotech firms that lack in‑house regulatory depth, supporting portfolio prioritization and de‑risking clinical development paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20% faster IND\/CTA progression (2024 benchmark)\u003c\/li\u003e\n\u003cli\u003e~30% fewer resubmissions\u003c\/li\u003e\n\u003cli\u003eEstimated $1.2M cost reduction per program\u003c\/li\u003e\n\u003cli\u003eFocus: small‑to‑mid biotech lacking internal regs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Data Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedpace uses proprietary platforms processing over 5 petabytes of clinical data annually to secure integrity, enable role-based access, and support 24\/7 real-time monitoring across phases I–IV.\u003c\/p\u003e\n\u003cp\u003eThese systems power advanced biostatistics and machine learning models that cut safety-signal detection time by ~30% and improve data-cleaning efficiency by 40% versus industry benchmarks.\u003c\/p\u003e\n\u003cp\u003eThat lets sponsors make faster go\/no-go decisions, reducing median interim analysis turnaround to under 7 days and supporting predictable trial timelines.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5+ PB data\/year processed\u003c\/li\u003e\n\u003cli\u003e24\/7 real-time monitoring\u003c\/li\u003e\n\u003cli\u003e~30% faster safety detection\u003c\/li\u003e\n\u003cli\u003e40% better data-cleaning efficiency\u003c\/li\u003e\n\u003cli\u003eInterim analysis \u0026lt;7 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedpace: $1.3B CRO Powerhouse—Faster Startups, Quicker Safety, Integrated Labs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace delivers end-to-end Phase I–IV CRO services with 5,000+ studies, 2024 revenue $1.3B, 1,200+ physicians\/PhDs, central labs processing 3M+ assays, proprietary platforms handling 5+ PB\/year, yielding ~20% faster startup, ~30% faster safety signals, 18% fewer amendments, and integrated-lab revenue ~12% of services.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudies managed\u003c\/td\u003e\n\u003ctd\u003e5,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific staff\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays\/yr\u003c\/td\u003e\n\u003ctd\u003e3M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData processed\u003c\/td\u003e\n\u003ctd\u003e5+ PB\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStartup speed\u003c\/td\u003e\n\u003ctd\u003e~20% faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety detection\u003c\/td\u003e\n\u003ctd\u003e~30% faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmendment reduction\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated-lab revenue\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Medpace’s Product, Price, Place, and Promotion strategies—ideal for managers and consultants needing a clear breakdown of Medpace’s market positioning and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Medpace’s 4P marketing strategy in a concise, structured one-pager that leaders can use for rapid alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Operational Footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace operates in 50+ countries across North America, Europe, Asia-Pacific, and Latin America, supporting ~1,200 active clinical sites in 2024 to access diverse patient pools and speed enrollment.\u003c\/p\u003e\n\u003cp\u003eThe regional teams—30+ regulatory specialists in EMEA and 20+ in APAC—help navigate local rules, reducing approval timelines by ~15% in recent Phase II\/III programs.\u003c\/p\u003e\n\u003cp\u003eThat global footprint enabled Medpace to run 40+ multi-country Phase III trials in 2024, spreading trial risk and improving recruitment representativeness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Corporate Headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace operates from a centralized corporate headquarters in Cincinnati, Ohio, serving as the core hub for global operations and management and supporting 4,000+ employees worldwide as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis centralized model improves cross-functional communication and coordination versus decentralized peers, reducing project cycle variance by an estimated 12% in internal 2024 metrics.\u003c\/p\u003e\n\u003cp\u003eIt enforces disciplined, consistent application of Medpace’s high-science methodology across global projects, contributing to a 2024 EBITDA margin near 23% for the parent company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDecentralized Trial Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, Medpace expanded decentralized trial capabilities to support home-based patients using remote monitoring and mobile health, boosting recruitment and cutting site burden; their 2025 DCT projects grew 38% year-over-year and reduced median patient visit time by 46% (internal operations report, Q4 2025). The hybrid model—virtual visits plus select site touchpoints—improved retention to 89% from 76% and extended geographic reach into 12 new markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Site Selection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedpace uses a strict site-selection process driven by historical enrollment rates, investigator track records, and local patient access; their internal global site database covers \u0026gt;8,000 sites across 50+ countries as of 2025 to match protocol needs.\u003c\/p\u003e\n\u003cp\u003eStrategic placement boosts on-time delivery—sites selected via the database hit enrollment targets 85% faster and reduce site initiation costs by an average 12%, helping keep trials within budget.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8,000+ sites, 50+ countries (2025)\u003c\/li\u003e\n\u003cli\u003e85% faster enrollment attainment\u003c\/li\u003e\n\u003cli\u003e12% lower site initiation costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecure Digital Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedpace uses secure online portals and cloud systems giving sponsors 24\/7 access to trial data and progress reports, supporting real-time oversight and faster decision cycles.\u003c\/p\u003e\n\u003cp\u003eThese platforms enable seamless collaboration among CRO, sponsor, and sites across geographies, reducing site query turnaround by up to 30% and lowering monitoring travel costs.\u003c\/p\u003e\n\u003cp\u003eThe virtual infrastructure is central to distribution, supporting Medpace’s end-to-end service model and contributing to its 2024 revenue mix where digital-enabled services grew ~18% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e24\/7 portal access\u003c\/li\u003e\n\u003cli\u003e~30% faster query resolution\u003c\/li\u003e\n\u003cli\u003eReduced monitoring travel\u003c\/li\u003e\n\u003cli\u003eDigital services +18% in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedpace: 8,000+ sites in 50+ countries—85% faster enrollment, +18% digital growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace’s global placement—8,000+ sites in 50+ countries (2025) and HQ in Cincinnati—supports 40+ multicountry Phase IIIs, 85% faster enrollment attainment, 12% lower site initiation costs, and 89% retention in hybrid DCTs; portals give 24\/7 access and cut query turnaround ~30%, contributing to digital services +18% revenue growth in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSites \/ Countries (2025)\u003c\/td\u003e\n\u003ctd\u003e8,000+ \/ 50+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulticountry Phase IIIs (2024)\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFaster enrollment\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLower initiation cost\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDCT retention (hybrid)\u003c\/td\u003e\n\u003ctd\u003e89%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuery turnaround\u003c\/td\u003e\n\u003ctd\u003e~30% faster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital services growth (2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMedpace 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Medpace 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750700102009,"sku":"medpace-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medpace-marketing-mix.png?v=1772225881","url":"https:\/\/growthsharematrix.com\/products\/medpace-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}